Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Marstacimab→

Marstacimab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1985638-39-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Tissue factor pathway inhibitor (TFPI) monoclonal antibodyprocoagulant biologic
Mechanism of action
Binds the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), reducing TFPI-mediated inhibition of factor Xa and the tissue factor-factor VIIa complex and increasing thrombin generation.
Indications / reported uses
  • Routine prophylaxis to prevent or reduce bleeding episodes in eligible adults and adolescent males aged 12 years and older with haemophilia A or B without factor VIII or IX inhibitors under the US HYMPTAVZI indication; not for treatment of acute bleeding

Sources: US DailyMed — HYMPTAVZI (marstacimab-hncq) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Marstacimab Environmental Risk Assessment (ERA) (the Marstacimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.